New Treatment Shown to Reduce Heart Attacks

A new treatment designed to restore the endothelium's normal ability to resist clot formation has been shown to significantly reduce the incidence of heart attacks and hospitalization for heart attacks.

Bruce A. Daniels, M.D., who invented the treatment, plans to introduce it as a dietary supplement for the prevention and treatment of cardiovascular disease, following clinical studies that confirm its benefits. After conducting extensive research into the causes of cardiovascular disease, Dr. Daniels concluded that preventing inflammation and other molecular changes was the key to prevention. Following more research, he theorized that cardiovascular disease results from the dysfunction of the arterial endothelium's ability to sustain production of effective levels of nitric oxide and anticoagulant heparins, which are normally protective substances.

As a result, Dr. Daniels developed a compound called Endovase, a treatment that contains only substances normally present in the body. Comparing his results in a 12-month retrospective study with the results of a study published in The American Journal of Cardiology for patients with unstable angina treated with invasive procedures showed that Endovase reduced hospitalization 90%, reduced the incidence of heart attacks by more than 90%, reduced the death rate by 95%, and reduced the need for repeated invasive procedures by 90%.

Dr. Daniels is chief medical and scientific officer for EndoMatrix (Napa, CA, USA), a biotechnology company commercializing Endovase and other products. "By treating the arteries themselves rather than just the blood coursing through them, we can prevent strokes and heart attacks far more effectively than by opening or bypassing a blockage in a few grossly involved areas,” said Dr. Daniels.





Related Links:
EndoMatrix